3527-19-3

Usage

Uses

Used in Pharmaceutical Industry:
1H-Benzimidazol-5-amine,1,2-dimethyl-(9CI) is used as a building block for the synthesis of various pharmaceuticals due to its versatile reactivity and structural properties. Its potential biological activities, including anti-inflammatory, anti-cancer, and anti-microbial properties, make it a promising candidate for the development of new drugs.
Used in Agrochemical Industry:
In the agrochemical industry, 1H-Benzimidazol-5-amine,1,2-dimethyl-(9CI) is utilized as a key intermediate in the synthesis of various agrochemicals. Its unique chemical structure and reactivity contribute to the development of effective pesticides and other agricultural chemicals.
Used in Research and Development:
1H-Benzimidazol-5-amine,1,2-dimethyl-(9CI) is employed as a valuable compound in research and development for its potential biological activities. Its anti-inflammatory, anti-cancer, and anti-microbial properties make it an attractive subject for further investigation and exploration of new therapeutic applications.

Upstream product

• 49819-79-6 1,2-dimethyl-5-nitro-1H-benzimidazole 
• 41939-61-1 N₁-methyl-4-nitrobenzene-1,2-diamine 
• 19492-66-1 1,2-dimethyl-6-nitro-1H-benzoimidazole 
• 2876-08-6 1,2-dimethyl-1H-benzimidazole 
• 95-54-5 1,2-diamino-benzene 
• 615-15-6 2-Methyl-1H-benzimidazole 
• 1792-40-1 2-methyl-5-nitrobenzimidazole 
• 364-73-8 4-Bromo-1-fluoro-2-nitrobenzene 
• 99513-17-4 5-bromo-1,2-dimethyl-1H-benzo[d]imidazole 
• 69038-76-2 2-N-methylamino-5-bromoaniline 
• 53484-26-7 N-methyl-4-bromo-2-nitroaniline 
• 369-36-8 6-fluoro-3-nitroaniline 
• 45869-07-6 N¹,N¹-dimethyl-benzene-1,2,4-triyltriamine 
• 108-24-7 acetic anhydride 

Downstream Products

• 920978-58-1 N-(1,2-dimethyl-1H-benzimidazol-5-yl)-5-chloro-1-[(3-fluorophenyl)methyl]-1H-pyrrolo[2,3-c]pyridine-2-carboxamide 
• 920978-71-8 N-(1,2-dimethyl-1H-benzimidazol-5-yl)-5-trifluoromethyl-1-[(3-fluorophenyl)methyl]-1H-pyrrolo[2,3-b]pyridine-2-carboxamide 
• 920978-62-7 N-(1,2-dimethyl-1H-benzimidazol-5-yl)-5-phenyl-1-[(3-fluorophenyl)methyl]-1H-pyrrolo[2,3-c]pyridine-2-carboxamide 
• 920978-78-5 N-(1,2-dimethyl-1H-benzimidazol-5-yl)-5-trifluoromethyl-1-[(3-fluorophenyl)methyl]-1H-pyrrolo[3,2-b]pyridine-2-carboxamide 
• 444731-57-1 3-({4-[(1,2-dimethyl-1H-benzimidazol-5-yl)(methyl)amino]pyrimidin-2-yl}amino)benzenesulfonamide 
• 1352942-35-8 1,2-dimethyl-5-(phthaloyl-L-phenylalanyl)-aminobenzimidazole 
• 1352942-41-6 1,2-dimethyl-5-(L-phenylalanyl)-amino benzimidazole 
• 920978-88-7 N-(1,2-dimethyl-1H-benzimidazol-5-yl)-1-[(3-fluorophenyl)methyl]-1H-pyrrolo[2,3-c]pyridine-2-carboxamide 
• 686747-26-2 5-amino-4-chloro-1,2-dimethylbenzimidazole 
• 17681-45-7 5-Amino-1,2-dimethylimidazo<5,4-g>benzothiazole 

Relevant academic research and scientific papers

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

Substituted heteroaryl compounds and compositions and uses thereof (by machine translation)

The invention discloses substituted heteroaryl compounds and compositions thereof and their use. The compounds of formula (I) compound or type shown in (I) a compound represented by stereo isomers, tautomers, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt or its prodrug. The invention also provides a pharmaceutical composition, the compounds and pharmaceutical compositions can be regulated protein kinase, particularly Aurora kinase and JAK kinase activity, for the prevention, treatment, treatment and reduce protein kinase, in particular JAK kinase activity mediated diseases or disorders. (by machine translation)

Crystal form of pyrimidine derivative

The invention relates to a pyrimidine derivative crystal form, in particular to a crystal form of a compound of formula (I) as shown in the specification, and a medicine composition of the crystal form, further to application of the crystal form or the me

Pyrimidineamines as angiogenesis modulators

Pyrimidine derivatives, which are useful as VEGFR2 inhibitors are described herein. The described invention also includes methods of making such pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

New antibacterial diazotized derivatives of 5-amino azaheterocycles

Six new diazotized derivatives of pharmacologically important azaheterocycles (2a-d, 4a-b) were prepared from their corresponding 5-amino benzimidazoles (1a-d) and benzimidazolones (3a-b). All new compounds have been characterized on the basis of their IR, NMR and Mass spectral data. Antibacterial activity of these compounds is also been reported.

New antibacterial peptide analogs of 5-Aminobenzimidazoles

Three new peptide analogs 5a-c were obtained through coupling of 5-Amino benzimidazoles 2a-c with L-phenylalanine. For the purpose α-amino group was blocked with phthalic anhydride and activation of α-carboxy group of phenylalanine was carried out by preparing phthaloyl-L-phenylalanyl chloride 4. After developing a successful peptide linkage, the phthaloyl group was removed by treating 5a-c with hydrazine hydrate to get free peptides 6a-c, purified through a column of Amberlite (IR-4B). All of these compounds 2a-c and 5,6a-c have been characterized on the basis of their IR, 1H NMR and EIMS analyses. Antibacterial activity of these compounds is also been reported.

INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AND TYPE 2

There is provided a compound having Formula (I): wherein one of R1 and R2 is a group of the Formula (a), wherein R4 is selected from H and hydrocarbyl, R5 is a hydrocarbyl group and L is an optional linker group, or R1 and R2 together form a ring substituted with the group (Formula (a)) wherein R3 is H or a substituent, and wherein X is selected from S, O, NR6 and C(R7)(R8), wherein R6 is selected from H and hydrocarbyl groups, wherein each of R7 and R8 are independently selected from H and hydrocarbyl groups.